DSS - DSS stock pops on licensing deal with ProPhase Labs

• DSS ( NYSE: DSS ) shares popped around 17% after the company announced on Thursday the licensing of Impact BioMedical's Linebacker portfolio to ProPhase Labs ( NASDAQ: PRPH ).
• Global BioLife, a subsidiary of DSS's wholly-owned subsidiary Impact BioMedical, signed a license deal with ProPhase Labs ( PRPH ) subsidiary ProPhase BioPharma. The deal involves the license of Global BioLife's Linebacker portfolio (LB-1 and LB-2), two patented small molecule PIM kinase inhibitors with significant potential across multiple therapeutic indications.
• LineBacker is expected to be effective in crossing the blood-brain barrier and would be delivered orally. Significant pre-clinical testing has been completed in neurology, anti-inflammatory, oncology, anti-infective, and viral disease states to demonstrate response to LineBacker.
• The deal marks DSS's second license agreement with ProPhase this year.

For further details see: